Objective: To estimate the prevalence of metabolically healthy obesity (MHO) according to different definitions. Methods: Population-based sample of 2803 women and 2557 men participated in the study. Metabolic abnormalities were defined using six sets of criteria, which included different combinations of the following: waist; blood pressure; total, high-density lipoprotein or low-density lipoprotein-cholesterol; triglycerides; fasting glucose; homeostasis model assessment; high-sensitivity C-reactive protein; personal history of cardiovascular, respiratory or metabolic diseases. For each set, prevalence of MHO was assessed for body mass index (BMI); waist or percent body fat. Results: Among obese (BMI X30 kg/m 2 ) participants, prevalence of MHO ranged between 3.3 and 32.1% in men and between 11.4 and 43.3% in women according to the criteria used. Using abdominal obesity, prevalence of MHO ranged between 5.7 and 36.7% (men) and 12.2 and 57.5% (women). Using percent body fat led to a prevalence of MHO ranging between 6.4 and 43.1% (men) and 12.0 and 55.5% (women). MHO participants had a lower odd of presenting a family history of type 2 diabetes. After multivariate adjustment, the odds of presenting with MHO decreased with increasing age, whereas no relationship was found with gender, alcohol consumption or tobacco smoking using most sets of criteria. Physical activity was positively related, whereas increased waist was negatively related with BMI-defined MHO. Conclusion: MHO prevalence varies considerably according to the criteria used, underscoring the need for a standard definition of this metabolic entity. Physical activity increases the likelihood of presenting with MHO, and MHO is associated with a lower prevalence of family history of type 2 diabetes.
Introduction
In the last decade, the worldwide prevalence of obesity has increased considerably, and so has the incidence of type 2 diabetes and cardiovascular disease (CVD) (Seidell, 2000; Kelly et al., 2008) . Several studies have shown that the obese phenotype may be present without metabolic abnormalities (Karelis, 2008; Karelis and Rabasa-Lhoret, 2008; Stefan et al., 2008; Wildman et al., 2008) . This clinical condition, termed benign obesity or metabolically healthy obesity (MHO), is restricted to a unique subset of the obese population which, despite excessive body mass index (BMI) or body fat, are insulin sensitive and have a normal blood pressure, lipid, inflammation and hormonal profile Karelis, 2008; Stefan et al., 2008; Wildman et al., 2008) . Among US obese adults, 29.2% of men and 35.4% of women (a total of approximately 19.5 million adults) are metabolically healthy. On the other hand, apparently 30.1% of normalweight men and 21.1% of normal-weight women (a total of approximately 16.3 million adults) are metabolically abnormal (Wildman et al., 2008) .
There are currently no unique criteria for MHO, and several definitions have been proposed (Meigs et al., 2006; Aguilar-Salinas et al., 2008; Karelis, 2008; Wildman et al., 2008; Lynch et al., 2009) . The criteria used to define MHO are summarized in Table 1 . Most authors use blood pressure, lipids (mainly high-density lipoprotein-cholesterol and/or triglycerides) and glycaemic status (fasting blood glucose or homeostasis model assessment) to define MHO, although other clinical or biological data are also used. Still, to our knowledge, there are no studies comparing the prevalence of MHO using the different definitions indicated previously. So, the purpose of our study was to assess the prevalence of MHO using several different definitions and to characterize the clinical and metabolic factors associated with MHO in a population-based sample of the Swiss adult population.
Participants and methods

Recruitment
The CoLaus Study was approved by the Institutional Ethics Committee of the University of Lausanne. The CoLaus Study is a cross-sectional study aimed at assessing the prevalence and deciphering the molecular determinants of cardiovascular risk factors in the Caucasian population of Lausanne, Switzerland, a town of 117 161 inhabitants, of which 79 420 are of a Swiss nationality.
The sampling procedure of the CoLaus Study has been described previously (Firmann et al., 2008) . Briefly, the complete list of Lausanne inhabitants aged 35-75 years (n ¼ 56 694) was provided by the population registry of the city. A simple, nonstratified random sample of 35% of the overall population was drawn. The following inclusion criteria were applied: (a) written informed consent; (b) age 35-75 years; (c) willingness to take part in the examination and donate blood sample; (d) Caucasian origin. Recruitment began in June 2003 and ended in May 2006. Participation rate was 41%.
All participants attended the outpatient clinic of the University Hospital of Lausanne in the morning after an overnight fast. Data were collected by trained field interviewers in a single visit lasting about 60 min.
Family data
Participants were asked about family history of acute myocardial infarction, hypertension, hypercholesterolemia and diabetes among their parents and their brothers/sisters. Personal history of CVD was assessed if the participant reported a self-reported diagnosis of coronary heart disease (angina, myocardial infarction, coronary revascularization), stroke or peripheral arterial disease. Personal history of respiratory disease was assessed if the participant reported a diagnosis of emphysema, asthma, chronic obstructive bronchitis or lung cancer; personal history of metabolic disease was assessed if the participant reported a diagnosis of hypo or hyperthyroidism.
Behavioral data According to their smoking histories, participants were classified as never, current or former smokers. Personal medicines, including prescribed and self-prescribed drugs were collected, together with their main indications.
Participants reported whether they currently consumed alcohol and how many standard drinks they had consumed in the past 7 days, using the same method as other studies (Marques-Vidal et al., 1995 , 2001 . A standard drink was defined as a glass of wine, a bottle of beer or a shot of spirits. Participants were then categorized according to the number of drinks per week: none, 1-6, 7-13 and X14 drinks/week. Physical activity was assessed by questions focusing on walking and other types of exercises in minutes per week. A participant was considered as physically active if he/she reported practicing at least 2 h of leisure-time physical activity per week. Participants were also asked if they had been told previously they were overweight or obese during childhood (10 years) and early adulthood (20-30 years) .
Clinical data
Body weight and height were measured with participants standing without shoes in light indoor clothes. Body weight was measured in kilograms to the nearest 100 g using a Seca scale, which was calibrated regularly. Height was measured to the nearest 5 mm using a Seca height gauge. Overweight was defined as a BMI X25 and o30 kg m
À2
; obesity was defined as a BMI X30 kg m
. Waist was measured with a nonstretchable tape over the unclothed abdomen at the navel. Two measures were made and the mean (expressed in centimetres) used for analyses. Abdominal obesity was considered for a waist 4102 cm for men and 488 cm for women (Lean et al., 1995) .
Body composition was assessed by electrical bioelectrical impedance analysis using the Bodystat 1500 analyzer (Isle of Man, UK). This device has been validated against reference methods (Ghosh et al., 1997) and its results have been shown to be more accurate than those obtained using a dual frequency bioelectrical impedance analysis device (Simpson et al., 2001) . The coefficient of variation for repeated measurements of electrical impedance is 0.7% (Steiner et al., 2002) ; the reproducibility has been shown to be between 1 and 5% (Martin et al., 2001) , and its correlation with reference methods such as isotope dilution is between 0.855 (Martin et al., 2001) and 0.96 (Simpson et al., 2001) . Participants had to fast for at least 5 h, not engage into strenuous physical activity the previous 12 h and abstain from consuming caffeine or alcohol-containing beverages 24 h before the analysis. Obesity was considered when body fat percentage was 440% for women or 428% for men .
Blood pressure was measured three times on the left arm after at least 10 min rest in the seated position using a clinically validated automated oscillometric sphygmomanometer (Omron HEM-907, Matsusaka, Japan), with an appropriately sized cuff. The average of the last two readings was used for analyses.
Biological data
Venous blood samples (50 ml) were drawn in the fasting state. All measurements were conducted using a Modular P apparatus (Roche Diagnostics, Rotkreuz, Switzerland) by the Clinical Laboratory of the Centre Hospitalier Universitaire Vaudois. The following analytical procedures (with maximum inter and intra-batch coefficient of variance) were used: total cholesterol by CHOD-PAP (1.6-1.7%); high-density lipoprotein-cholesterol by CHOD-PAP þ PEG þ cyclodextrin (3.6-0.9%); triglycerides by GPO-PAP (2.9-1.5%); highsensitive C-reactive protein by immunoassay and latex HS (HS Latex; Diagnostic Products Corporation, Los Angeles, CA, USA, 4.6-1.3%); glucose by glucose dehydrogenase (2.1-1.0%). Insulin was assessed by a solid-phase, two-site chemiluminescent immunometric assay (Diagnostic Products Corporation, Los Angeles, USA) with a maximum intra-assay coefficient of variance of 13.7%. Low-density lipoprotein was calculated using the Friedewald formula. Homeostasis model assessment was used to evaluate insulin resistance using the following formula: fasting serum insulin level Â fasting plasma glucose level/22.5.
Determination of the prevalence of metabolically healthy obese
The diagnosis of MHO was obtained based on the joint combination of each obesity marker (BMI, waist circumference and body fat percentage) and six different sets of cardiometabolic abnormalities (Karelis et al., 2004; Meigs et al., 2006; Aguilar-Salinas et al., 2008; Wildman et al., 2008; Lynch et al., 2009) (Table 1 ). There were no exclusion criteria such as menopause, hormonal use and medications affecting metabolism, as well as diabetes and CVDs; participants were selected if they presented with overweight or obesity using the different anthropometric markers (BMI, waist or body fat).
Statistical analysis
Statistical analysis was conducted using SPSS v.13.0 (SPSS, Chicago, IL, USA) and SAS (SAS, Cary, NC, USA). Quantitative variables were expressed as mean ± s.d. and qualitative variables as number of participants and (percentage). Bivariate comparisons were performed using Student's t-test or w 2 -test for quantitative and qualitative variables, respectively. Multivariate logistic regression analysis was performed using age, gender, smoking status, alcohol consumption, physical activity and waist circumference as suggested (Wildman et al., 2008) . Multivariate analysis was conducted among obese participants only and after pooling obese and overweight participants as suggested (Wildman et al., 2008) . Statistical significance was considered for Po0.05.
Results
Clinical characteristics
Of the initial 6188 participants, 5356 (86.6%, 2799 women and 2557 men) had data for both sets of metabolic abnormalities and were thus eligible for analysis. Table 2 summarizes the clinical characteristics of the participants according to gender. Men were younger, presented a higher BMI, waist and hip circumference, but a lower body fat percentage than women. Men had also a higher level of education, drank and smoked more. Finally, women presented a higher frequency leisure-time physical activity.
Prevalence of MHO Among obese (BMI X30 kg/m 2 ) participants, prevalence of MHO ranged between 3.3 and 32.1% in men and between 11.4 and 43.3% in women according to the criteria used. Using abdominal obesity, prevalence of MHO ranged between 5.7 and 36.7% (men) and between 12.2 and 57.5% (women). Using percent body fat led to a prevalence of MHO ranging between 6.4 and 43.1% (men) and 12.0 and 55.5% (women). Prevalence of MHO was higher in women ( Figure 1 ) and decreased with age in both genders (Figure 2 ). Circa 60% of obese (BMI-defined) subjects were considered at least once as MHO, this percentage increasing to 70% when abdominal obesity was used. Conversely, less than 5% of all obese subjects were considered as MHO by all six definitions used and irrespective of the anthropometric markers used.
MHO participants tended to present a lower prevalence of family history of type 2 diabetes, and this difference was confirmed by multivariate logistic regression adjusting for gender, age, smoking, drinking and physical activity (Table 3) . MHO participants also tended to present a lower frequency of personal history of CVD, but this difference was no longer significant after multivariate adjustment. Using waist to define obesity led to similar results, that is, a lower prevalence of family history of type 2 diabetes among non-MHO participants, who also tended to present a lower frequency of personal history of CVD (Table 3) . Finally, no differences were found between MHO and non-MHO participants regarding the age of obesity onset (Supplementary Figure) .
Correlates of MHO
The results of a multivariate logistic regression restricted to metabolically healthy overweight and/or obese participants according to the different definition of MHO are Figure 1 Prevalence of metabolically healthy obesity according to different criteria (see Table 1 for details), stratified by gender. Prevalence of metabolically healthy obesity S Velho et al summarized in Table 4a (for obesity only) and Table 4b (for obesity þ overweight). Overall, no difference was found between genders regarding the prevalence of MHO. The odds of presenting with MHO decreased with increasing age, whereas no relationship was found with alcohol consumption or tobacco smoking. Physical activity was positively related with MHO, whereas increased waist was negatively related with MHO in most cases (Table 4a ). Further analysis pooling overweight and obese subjects showed similar results, that is, a positive relationship of physical activity and a negative relationship of increased age or waist with MHO (Table 4b ).
Discussion
To our knowledge, there have been few, if no, studies comparing the prevalence of MHO using different definitions in the general population. Our findings suggest that the prevalence of MHO varies considerably according to the obesity markers and the criteria used to define metabolic abnormalities, thus raising the question of which criteria and obesity markers to use, and the comparability between studies. Furthermore, o5% of all obese subjects (irrespective of the anthropometric marker used to define obesity) were considered as MHO by all six definitions used, a finding also reported in another study, where no MHO subject was identified within the five methods used (Messier et al., 2009 Using BMI to define obesity, the prevalence of MHO was lower than reported in other studies (Figure 3 ). An exception was the prevalence of MHO in women defined by the criteria of Karelis et al. (2004) , which showed a good agreement with the previously published data. No comparison could be made for obese men using the same criteria, as the previous study was conducted in a sample of postmenopausal women. The fact that the prevalence of MHO in this study was lower than reported in the other studies might be due to the older age of our sample (mean age 53. (2008)). As the prevalence of metabolic abnormalities increases with age (Adams et al., 2006) , the higher age of our sample might have decreased the prevalence of MHO. Indeed, in our study, the prevalence of MHO decreased with age irrespective of the obesity marker or the criteria used to define MHO. Another likely explanation is the fact that our study only included Caucasians, as the MHO phenotype was found by Wildman to be more prevalent in non-Hispanic blacks (Wildman et al., 2008) .
Compared with BMI-derived obesity, a higher prevalence of MHO was found when abdominal obesity was used. This result may be due to a higher prevalence of abdominal obesity compared with BMI-derived obesity in the Swiss population (Marques-Vidal et al., 2008a) . The presence of abdominal obesity was also associated with decreased odds of presenting with MHO, indicating that visceral fat might be more related to metabolic abnormalities than BMI, as suggested previously (Lean et al., 1995; Janssen et al., 2004) .
The highest prevalence of MHO was obtained when % body fat was used. Those findings should be considered with some caution, as there are no internationally agreed-upon cut-offs for body fat to define obesity (Marques-Vidal et al., 2008b) . Indeed, changing the threshold of body fat percent to define obesity led to differences in the percentage of MHO (Supplementary Table) . Hence, we do not recommend for the time being the use of % body fat to define MHO; BMI or waist should be preferred instead. Although some authors have advocated that waist should not be used to define MHO because most obese subjects also present with a high waist Figure 2 Prevalence of metabolically healthy obesity according to different criteria (see Table 1 Prevalence of metabolically healthy obesity S Velho et al Results are expressed as number of subjects and (percentage) or as odds ratio and (95% confidence interval) adjusting for gender, age, smoking, drinking and physical activity. Statistical analysis by w 2 or logistic regression. MHO was defined using different criteria (see Table 1 for details). Results are expressed as odds ratio and (95% confidence interval). Metabolic abnormalities were defined using different criteria (see Table 1 for details). Prevalence of metabolically healthy obesity S Velho et al (Messier et al., 2009) , still our data suggest that an increased waist is negatively related with MHO among BMI-defined obese subjects. Nevertheless, the wide range of MHO prevalence according to the set of criteria used observed in this study stresses the need for an expert consensus to standardize the identification of MHO subjects, as suggested previously (Messier et al., 2009) . According to the criteria presented in Table 1 , a possible set of criteria to define MHO would include insulin resistance (fasting plasma glucose or homeostasis model assessment), blood pressure and lipid (triglycerides or high-density lipoprotein-cholesterol) markers, the inclusion of other markers such as C-reactive protein or waist needing further investigation. Some authors have suggested that MHO is associated with an earlier age-related obesity onset (Brochu et al., 2001) . Hence, it could be argued that early-onset of obesity might lead to an increased prevalence of metabolic abnormalities, MHO participants actually becoming obese at an older age than their metabolically abnormal counterparts. Still, this hypothesis is not substantiated in this study, as MHO participants tended to report more frequently being told they were overweight and/or obese at an earlier age, albeit this difference was not statistically significant. These contradictory assumptions clearly show the need for more research on the definition of MHO and to establish the temporal sequence of obesity and obesity-related comorbidities onset. We speculate that MHO might not be due to a longer obesity period, but be possibly associated to a specific genotype or other clinical or behavioral characteristics (Rissanen et al., 2002) , as a lower prevalence of family history of type 2 Results are expressed as odds ratio and (95% confidence interval). Metabolic abnormalities were defined using different criteria (see Table 1 for details). Figure 3 Prevalence of metabolically healthy obesity according to different criteria (see Table 1 for details) in this study and as reported in the literature. Results are expressed as percentage of obese participants. a Using metabolic syndrome variables; b using homeostasis model assessment only; *women only.
Prevalence of metabolically healthy obesity S Velho et al diabetes and CVD (albeit no longer significant after multivariate adjustment) was found among MHO. MHO could potentially be an important subtype of obesity also if longitudinal data show that the outcome of complications of obesity are less in this subset.
In agreement with a previous study (Wildman et al., 2008) , several lifestyle markers were independently and significantly related with MHO. For instance, participants engaging in physical activity had higher odds of presenting with MHO, indicating that physical activity exerts beneficial effects on cardiovascular risk factors even among obese participants, a finding already known (Messier et al., 2008) . Conversely, and contrary to a previous study (Wildman et al., 2008) , no relationship was found between alcohol consumption and MHO, possibly due to the fact that a high alcohol consumption was associated with increased blood pressure (Foerster et al., 2009) . Also, no relationship between MHO and smoking status was found, with the exception of MHO among overweight þ obese subjects using the criteria of Wildman et al. (2008) . A possible explanation is that the effect of smoking might be related to increased hs-C-reactive protein values rather than to the changes of the other metabolic markers (Yanbaeva et al., 2007) . Indeed, in this study, smokers presented with higher hs-C-reactive protein levels than former or non-smokers (2.69 ± 3.50 vs 2.49 ± 3.45 and 2.53 ± 3.63 mg/l, respectively, analysis of variance on log-transformed variables Po0.005).
This study has several limitations worth pointing out. The participation rate was low (41%), which might limit the generalization of the findings; however, this participation rate is similar to other epidemiological studies (Wolf et al., 1998) . Also, no data on non-Caucasian participants were available; therefore, our findings may not apply to other ethnicities, as it has been suggested that other BMI and waist thresholds should be used (Deurenberg, 2001) . It is also worth indicating that no retrospective data regarding height and weight was available, albeit it has been shown that selfreported measure of family history of obesity is valid (Paradis et al., 2008) . Finally, no MHO classification could be performed using more sophisticated methods to identify insulin resistance such as the gold standard hyperinsulinemic-euglycemic clamp technique (Karelis et al., 2005) or the Matsuda index (Stefan et al., 2008) . The major strength of our study is that we used a population-based sample representative of the Swiss population, and that a precise characterization of the participants was performed. Furthermore, the ongoing follow-up of this cohort will enable to check if MHO participants maintain their status with increasing time of obesity.
In summary, our data indicate that the prevalence of MHO varies considerably according to both to the set of criteria used to define metabolic abnormalities and to the anthropometric marker used to define obesity, urging the need for a standard definition of this metabolic entity. Among obese subjects, physical activity increases the likelihood of presenting with MHO. The rationale for lower prevalence of type 2 diabetes in the families of MHO participants awaits further investigation.
